[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 463, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 59, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 2546665, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 51, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 52, "title": "Senior VP & CFO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 58, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 67, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 58, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 57, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 43, "title": "Senior VP & Chief Business Development Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.44, "open": 4.44, "dayLow": 4.371, "dayHigh": 4.515, "regularMarketPreviousClose": 4.44, "regularMarketOpen": 4.44, "regularMarketDayLow": 4.371, "regularMarketDayHigh": 4.515, "beta": 2.031, "forwardPE": -6.5735292, "volume": 414183, "regularMarketVolume": 414183, "averageVolume": 797406, "averageVolume10days": 1058560, "averageDailyVolume10Day": 1058560, "marketCap": 1189440128, "fiftyTwoWeekLow": 2.555, "fiftyTwoWeekHigh": 7.45, "priceToSalesTrailing12Months": 113.312386, "fiftyDayAverage": 3.9851, "twoHundredDayAverage": 4.7323, "currency": "USD", "enterpriseValue": 772187200, "floatShares": 131748688, "sharesOutstanding": 266094000, "sharesShort": 10094968, "sharesShortPriorMonth": 11427308, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0379, "heldPercentInsiders": 0.18025999, "heldPercentInstitutions": 0.75631, "shortRatio": 14.14, "shortPercentOfFloat": 0.0512, "impliedSharesOutstanding": 266094000, "bookValue": 1.984, "priceToBook": 2.253024, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -233982000, "trailingEps": -1.14, "forwardEps": -0.68, "enterpriseToRevenue": 73.563, "enterpriseToEbitda": -4.147, "52WeekChange": 0.66171, "SandP52WeekChange": 0.40128052, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.47, "targetHighPrice": 13.0, "targetLowPrice": 7.0, "targetMeanPrice": 10.4, "targetMedianPrice": 11.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 705939008, "totalCashPerShare": 2.653, "ebitda": -186211008, "totalDebt": 288684000, "quickRatio": 18.187, "currentRatio": 18.546, "totalRevenue": 10497000, "debtToEquity": 54.691, "revenuePerShare": 0.049, "returnOnAssets": -0.18497999, "returnOnEquity": -0.61804, "freeCashflow": -150120880, "operatingCashflow": -156618000, "operatingMargins": -18.39249, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]